5-amino-3-(2’-O-acetyl-3‘-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one | 892498-64-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-amino-3-(2’-O-acetyl-3‘-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one
• 英文别名: 5-amino-3-(2'-O-acetyl-3'-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one；5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyltetrahydrofuran-3-yl acetate；Qti86134YL；[(2R,3R,5S)-2-(5-amino-2-oxo-[1,3]thiazolo[4,5-d]pyrimidin-3-yl)-5-(hydroxymethyl)oxolan-3-yl] acetate
• CAS: 892498-64-5
• 化学式: C₁₂H₁₄N₄O₅S
• 分子量: 326.333
• InChiKey: HOOMGTNENMZAFP-NYNCVSEMSA-N

物化性质

• 沸点：
  622.1±65.0 °C(Predicted)
• 密度：
  1?+-.0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  153
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  5-amino-3-(2’-O-acetyl-3‘-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one 、 氯甲酸异丙酯 在 吡啶 作用下， 以 甲苯 为溶剂， 反应 10.75h， 以75%的产率得到[(2R,3R,5S)-2-(5-amino-2-oxo-[1,3]thiazolo[4,5-d]pyrimidin-3-yl)-5-(propan-2-yloxycarbonyloxymethyl)oxolan-3-yl] acetate
  参考文献：
  名称：

  WO2007/150002

  摘要：

  公开号：
• 作为产物：
  描述：

  3-脱氧-D-赤式呋喃戊糖三乙酸酯 在 N,O-双三甲硅基乙酰胺 、 lipozyme 435 作用下， 以 乙醇 、 甲苯 、 乙腈 为溶剂， 反应 47.5h， 生成 5-amino-3-(2’-O-acetyl-3‘-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one
  参考文献：
  名称：

  CO-CRYSTALS OF 5-AMINO-2-OXOTHIAZOLO[4,5-D]PYRIMIDIN-3(2H)-YL-5-HYDROXYMETHYL TETRAHYDROFURAN-3-YL ACETATE AND METHODS FOR PREPARING AND USING THE SAME

  摘要：

  Formula I化合物的共晶体及其药物组合物是治疗疾病的新型治疗药物，例如人类免疫缺陷病毒（HIV）感染、乙型肝炎病毒（HBV）感染、丙型肝炎病毒（HCV）感染和癌症。这些共晶体比Formula I化合物对应的对甲苯磺酸盐形式更稳定，对氧化和水解更稳定，具有更好的药代动力学特性和优越的生物活性。

  公开号：

  US20160176899A1

文献信息

• [EN] COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR<br/>[FR] TRAITEMENT COMBINÉ AVEC UN AGONISTE DE TLR7 ET UN INHIBITEUR D'ASSEMBLAGE DE CAPSIDE DU VIRUS DE L'HÉPATITE B
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016146598A1

  公开（公告）日：2016-09-22

  The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of a TLR7 agonist and an HBV capsid assembly inhibitor for use in the treatment of chronic hepatitis B patient.

  本发明涉及用于治疗乙型肝炎病毒感染的组合物和方法。具体地，本发明涉及一种联合疗法，包括给予TLR7激动剂和HBV壳蛋白组装抑制剂以用于治疗慢性乙型肝炎患者。
• [EN] COMBINATION THERAPY OF AN HBSAG INHIBITOR AND A TLR7 AGONIST<br/>[FR] POLYTHÉRAPIE À BASE D'UN INHIBITEUR DE HBSAG ET D'UN AGONISTE DE TLR7
  申请人：HOFFMANN LA ROCHE

  公开号：WO2017211791A1

  公开（公告）日：2017-12-14

  The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of an HBs Ag inhibitor and a TLR7 agonist for use in the treatment of chronic hepatitis B patient.

  本发明涉及用于治疗乙型肝炎病毒感染的组合物和方法。具体而言，本发明涉及一种组合疗法，包括给予HBs Ag抑制剂和TLR7激动剂，用于治疗慢性乙型肝炎患者。
• Prodrugs of 5-amino-3-(3'-deoxy-b-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione
  申请人：Haley J. Gregory

  公开号：US20080032999A1

  公开（公告）日：2008-02-07

  The invention is directed to 5-amino-3-(3′-deoxy-β-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione prodrugs, whose metabolized parent compound has immunomodulatory activity. The invention also relates to the therapeutic use of such prodrugs and pharmaceutical compositions thereof in treating disease states associated with abnormal cell growth, such as cancer.

  这项发明涉及5-氨基-3-(3'-去氧-β-D-核糖呋喃苷基)-噻唑并[4,5-d]嘧啶-2,7-二酮前药，其代谢后的母化合物具有免疫调节活性。该发明还涉及使用这种前药及其制剂治疗与异常细胞生长相关的疾病状态，如癌症。
• 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
  申请人：Webber Stephen E.

  公开号：US20110275589A1

  公开（公告）日：2011-11-10

  The invention is directed to 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and pharmaceutical compositions containing them, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds and prodrugs.

  本发明涉及具有免疫调节活性的3,5-二取代和3,5,7-三取代-3H-噁唑并[4,5-d]嘧啶-2-酮化合物及其前药。本发明还涉及使用此类化合物及其前药的治疗或预防用途，以及含有它们的制药组合物和通过给予这些化合物和前药的有效量来治疗本文所述疾病和疾病的方法。
• METHOD FOR PREPARING FURANOSE COMPOUNDS
  申请人：Kucera David

  公开号：US20110172447A1

  公开（公告）日：2011-07-14

  The present disclosure relates to p-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and to its use in treating conditions such as viral infections, tumors, and cancer. Also disclosed is a method of preparing the p-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and methods for producing furanose compounds which are useful intermediates in the preparation of pharmaceutical compounds such as p-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and the like.

  本公开涉及5-氨基-3-(2'-O-乙酰-3'-脱氧-β-D-核糖呋喃苷基)-3H-噻唑并[4,5-d]嘧啶-2-酮的对甲苯磺酸盐及其在治疗病毒感染、肿瘤和癌症等疾病中的应用。还公开了制备5-氨基-3-(2'-O-乙酰-3'-脱氧-β-D-核糖呋喃苷基)-3H-噻唑并[4,5-d]嘧啶-2-酮的对甲苯磺酸盐的方法，以及用于制备类似于对甲苯磺酸盐的药物化合物的呋喃糖中间体的方法。